Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Read our guide on Step Therapy Denials
Phase 2: Market Creation at Scale Novo Nordisk didnt just innovateit scaled demand aggressively: Positioned GLP-1 as a dual-solution drug (diabetes + weight loss) Expanded into non-diabetic populations seeking weight management Invested heavily in manufacturing and global supply chains Built direct-to-consumer channels to improve access By 2025: GLP-1 drugs became the primary growth driver for the company Novo Nordisk held a dominant share in the GLP-1 market Demand surged globally, driven by rising obesity and diabetes rates The broader GLP-1 market is now expected to grow at ~14% CAGR, driven by lifestyle diseases and expanding use cases
Our guide on supplements to take with GLP-1 medications covers this topic in detail
It has no MHRA or FDA marketing authorisation
US$ 26.98
US$ 22.86
US$ 28.25
US$ 25.19
